
Shreehas Tambe Appointed As CEO & MD Of Biocon; Kedar Upadhye Appointed As CFO
Biocon Limited has appointed Shreehas Tambe as Chief Executive Officer and Managing Director (CEO & MD), effective April 1, 2026, following Board and committee approvals. He will lead the combined platform after the integration of Biocon Biologics Limited as a wholly owned subsidiary.
The company also appointed Kedar Upadhye as Chief Financial Officer (CFO).
Tambe has been associated with Biocon for nearly three decades, starting as a management trainee and moving into leadership roles across businesses. He served as CEO & MD of Biocon Biologics Ltd., where he led the acquisition and integration of the Viatris biosimilars business and the expansion of global operations. He earlier held roles as Chief Operating Officer (COO) and Deputy CEO, overseeing enterprise operations and growth. He also led the development of the insulin business, including setting up a manufacturing facility in Malaysia. Tambe began his career in research and development and is listed on multiple patents. He holds a master’s degree from the Institute of Chemical Technology and has received industry awards.
Upadhye has worked on fundraising initiatives, including a bond issuance listed on the Singapore Exchange, and has supported balance sheet management and cash flow planning. Before this, he served as CFO at ReNew Energy Global. He has held roles at Cipla, Dr. Reddy’s Laboratories, PepsiCo, and Thermax. He has over 23 years of experience across corporate finance, strategy, and governance. He holds an MBA from the Indian Institute of Management Bangalore and is a qualified company secretary and cost accountant.




